Meta-analysis of Asymptomatic Monkeypox Virus Prevalence in Nonendemic Regions, 2022-2024.

Emerg Infect DisOct 1, 2026
Clinical ResearchInfectious Diseases

Kelsey J MacCuish, Robert Snyder, Kelly A Johnson et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the prevalence of asymptomatic monkeypox virus (MPXV) detections in nonendemic regions from May 2022 to September 2024. The study found a pooled prevalence of 1.0% (95% prediction interval 0.1%-11.2%) across various geographic regions and study designs, indicating a low but notable presence of asymptomatic cases.

Key findings

  • The pooled prevalence of asymptomatic MPXV detections was 1.0%.
  • The 95% prediction interval for prevalence ranged from 0.1% to 11.2%.
  • Prevalence did not significantly differ by geographic region or study design.

Why it matters

Understanding the prevalence of asymptomatic monkeypox cases is crucial for public health strategies, as it may influence monitoring and response efforts in nonendemic regions where the virus is emerging.

Source

PubMed · PMID 42810995

Published in Emerg Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.